Immunotherapy With Leukemia-cell-derived Heat Shock Protein 70 Triggers Induction Of Leukemia-specific Antibodies

Main Category: Cancer / Oncology
Also Included In: Lymphoma / Leukemia;  Clinical Trials / Drug Trials
Article Date: 24 Jul 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Even after chemotherapies and stem cell transplants, relapses still occur in leukemia patients. This study established a mouse model after bone marrow transplant and found that the immunization of mice with leukemia-cell-derived heat shock protein 70 (HSP) induced leukemia-specific immunities and prolonged their survival.

The tumor-derived-HSP binds the tumor-specific antigenic peptides, making it an effective cancer vaccination. It has reported that patients with peptide-specific antibodies survived longer than those without.

Using leukemia-specific antibodies induced by HSP-based vaccination would be useful for the prognosis of leukemia and facilitate the establishment of novel therapeutic strategies in the future.

"Induction of leukemia-specific anti-bodies by immunotherapy with leukemia-cell-derived heat shock protein 70"
Junko Jimbo, Kazuya Sato, Takaaki Hosoki, Motohiro Shindo, Katsuya Ikuta, Yoshihiro Torimoto, Yutaka Kohgo
Cancer Science - Volume 99 Issue 7, Pages 1427 - 1434
10.1111/j.1349-7006.2008.00829.x
Click here to view Abstract online

About Cancer Science

Cancer Science (formerly Japanese Journal of Cancer Research) aims to present research that has a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal publishes original articles and editorials, letters to the editor, review articles and reports describing original research in the fields of basic, translational and clinical cancer.

Subject categories include:
-- carcinogenesis
-- tumor biology and pathology
-- molecular biology and genetics
-- epidemiology and prevention
-- immunology and virology
-- experimental therapeutics
-- clinical medicine

www.blackwellpublishing.com/journal.asp?ref=1347-9032&site=1